# Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients

> **NCT05933031** · PHASE2 · UNKNOWN · sponsor: **HK inno.N Corporation** · enrollment: 381 (estimated)

## Conditions studied

- Helicobacter Pylori Infection

## Interventions

- **DRUG:** Tegoprazan 50 mg Triple Therapy
- **DRUG:** Tegoprazan 100 mg Triple Therapy
- **DRUG:** Lansoprazole Triple Therapy

## Key facts

- **NCT ID:** NCT05933031
- **Lead sponsor:** HK inno.N Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-27
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 381 (ESTIMATED)
- **Last updated:** 2023-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05933031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05933031, "Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05933031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*